Management ChangeNov 2, 2026, 04:32 PM
CollPlant Biotechnologies Appoints New CEO, Cuts R&D
AI Summary
CollPlant Biotechnologies Ltd. announced a significant management change and strategic shift. Yehiel Tal has stepped down as CEO and Interim Chairman, effective immediately, as part of a broader cost-reduction plan. Eran Rotem, previously Deputy CEO and CFO, has been appointed as the new CEO, while retaining his CFO role. The company is also discontinuing its regenerative medicine research and development activities to optimize operating expenses. However, the production and supply of recombinant human collagen (rhCollagen) and rhCollagen-based bioinks to business partners will continue.
Key Highlights
- Yehiel Tal ceases serving as CEO of CollPlant Biotechnologies, effective immediately.
- Eran Rotem appointed as the new CEO of CollPlant Biotechnologies, effective immediately.
- Rotem will continue to serve as CFO; compensation terms remain unchanged.
- Yehiel Tal resigns as Interim Chairman but will remain on the Board.
- Company is discontinuing regenerative medicine R&D activities as part of cost-reduction plan.
- Production of recombinant human collagen (rhCollagen) and bioinks will continue unaffected.
Price Impact
More from CLGN